Investors
Information Disclosure
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2024.01.05
-
VOLUNTARY ANNOUNCEMENT - "EVEROLIMUS TABLETS" SUCCEEDED IN PATENT CHALLENGE AND BECAME A FIRST-TO-MARKET GENERIC DRUG2024.01.03
-
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 20232024.01.02
-
VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW DRUG APPLICATION FOR KRAS G12C INHIBITOR "GARSORASIB TABLET (D-1553)"2024.01.02
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2024.01.02
-
VOLUNTARY ANNOUNCEMENT - APPROVAL OF CLINICAL TRIAL FOR INNOVATIVE MEDICINE "TRD205 (AT2R RECEPTOR ANTAGONIST)" TABLET2023.12.27
-
VOLUNTARY ANNOUNCEMENT - COMPLETION OF PATIENT ENROLLMENT IN PHASE III CLINICAL TRIAL OF ANLOTINIB (A CATEGORY I NNOVATIVE DRUG) COMBINED WITH CHEMOTHERAPY IN FIRST-LINE TREATMENT OF ADVANCED SOFT TISSUE SARCOMA2023.12.22
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2023.12.22